Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

By sjmartinez • April 19, 2024

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024 Apr 17;190(5):668-679. doi: 10.1093/bjd/ljae014. PMID: 38226713.

Tags: Dermatology, Olive View DoM, Publications

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF. Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial. JAMA[...]

UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes

Chen HC, Bang MF, Wang HH, Shpargel KB, Kohn LA, Sailer D, Zhang S, McCarthy EC, Seyedsadr M, Stevens S, Pham CLH, Zhou Z, Yin[...]

Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses

Thapa M, Green B, Kasperkiewicz M. Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses. JAAD Int. 2025 Oct 18;24:172-176. doi: 10.1016/j.jdin.2025.10.004. PMID:[...]